Paper
Organic & Biomolecular Chemistry
((6aR,7S,7aS)-1,4-Bis(4-(trifluoromethyl)phenyl)-6,6a,7,7a,8,9-
Notes and references
hexahydro-5H-cyclopropa[5,6]cycloocta[1,2-d]pyridazin-7-yl)metha-
nol (8). Compound 8 was prepared according to the general pro-
cedure and purified by column chromatography (DCM–MeOH,
50 : 1) to give a yellow solid (yield, 95%). 1H NMR (MeOD):
1.09–1.20 (m, 3H), 1.60–1.70 (m, 2H), 2.10–2.20 (m, 2H),
2.80–2.90 (m, 2H), 2.93–3.05 (m, 2H), 3.68 (d, 2H, J = 7.2 Hz),
7.76 (d, 4H, J = 8.0 Hz), 7.90 (d, 4H, J = 8.0 Hz). HRMS (ESI): m/z
calcd for C26H22F6N2O [M + H]+ 493.1715, found 493.1721.
((6aR,7S,7aS)-1,4-Bis(4-fluorophenyl)-6,6a,7,7a,8,9-hexahydro-
5H-cyclopropa[5,6]cycloocta[1,2-d]pyridazin-7-yl)methanol (10).
Compound 10 was prepared according to the general pro-
cedure and purified by column chromatography (DCM–MeOH,
50 : 1) to give a yellow solid (yield, 94%). 1H NMR (CDCl3): 0.80–0.90
(m, 3H), 1.30–1.40 (m, 2H), 1.40–1.70 (m, 2H) 2.40–2.50 (m, 2H),
2.70–2.80 (m, 2H), 2.88–2.95 (m, 2H), 3.44 (d, 2H, J = 6.8 Hz),
7.17–7.22 (m, 4H) 7.49–7.53 (m, 4H). HRMS (ESI): m/z calcd for
C24H22F2N2O [M + H]+ 393.1778, found 393.1762.
1 S. T. Laughlin, J. M. Baskin, S. L. Amacher and
C. R. Bertozzi, Science, 2008, 320, 664–667.
2 E. M. Sletten and C. R. Bertozzi, Angew. Chem., Int. Ed.,
2009, 48, 6974–6998.
3 M. D. Best, Biochemistry, 2009, 48, 6571–6584.
4 R. K. Lim and Q. Lin, Chem. Commun., 2010, 46, 1589–1600.
5 H. Stöckmann, A. A. Neves, H. A. Day, S. Stairs,
K. M. Brindle and F. J. Leeper, Chem. Commun., 2011, 47,
7203–7205.
6 X. Ning, J. Guo, M. A. Wolfert and G. J. Boons, Angew.
Chem., Int. Ed., 2008, 47, 2253–2255.
7 J. A. Codelli, J. M. Baskin, N. J. Agard and C. R. Bertozzi,
J. Am. Chem. Soc., 2008, 130, 11486–11493.
8 A. A. Poploukhtine, N. E. Mbua, M. A. Wolfert, G. J. Boons
and V. V. Popik, J. Am. Chem. Soc., 2009, 131, 15769–15776.
9 M. F. Debets, S. S. van Berkel, S. Schoffelen, F. P. Rutjes,
J. C. van Hest and F. L. van Delft, Chem. Commun., 2010,
46, 97–99.
4,4′-((6aR,7S,7aS)-7-(Hydroxymethyl)-6,6a,7,7a,8,9-hexahydro-
5H-cyclopropa[5,6]cycloocta[1,2-d]pyridazine-1,4-diyl)diphenol
(11). Compound 11 was prepared according to the general pro- 10 J. C. Jewett, E. M. Sletten and C. R. Bertozzi, J. Am. Chem.
cedure and purified by column chromatography (DCM–MeOH, Soc., 2010, 132, 3688–3690.
50 : 1) to give a yellow solid (yield, 92%). H NMR (DMSO-D6): 11 M. L. Blackman, M. Royzen and J. M. Fox, J. Am. Chem.
0.65–0.76 (m, 3H), 1.35–1.50 (m, 2H), 2.25–2.32 (m, 2H), Soc., 2008, 130, 13518–13519.
2.63–2.70 (m, 2H), 2.80–3.86 (m, 2H), 3.20 (dd, 2H, J1 = 5.6 Hz, 12 M. T. Taylor, M. L. Blackman, O. Dmitrenko and J. M. Fox,
J2 = 5.6 Hz), 4.40 (t, 1H, J = 5.6 Hz) 6.91 (d, 2H, J = 8.4 Hz), 7.33
J. Am. Chem. Soc., 2011, 133, 9646–9649.
(d, 2H, J = 8.4 Hz), 9.77 (s, 1H). HRMS (ESI): m/z calcd for 13 N. K. Devaraj, R. Upadhyay, J. B. Haun, S. A. Hilderbrand and
C24H24N2O3 [M + H]+ 389.1865, found 389.1862.
R. Weissleder, Angew. Chem., Int. Ed., 2009, 48, 7013–7016.
((6aR,7S,7aS)-1,4-Bis(4-methoxyphenyl)-6,6a,7,7a,8,9-hexahy- 14 M. F. Debets, J. C. van Hest and F. P. Rutjes, Org. Biomol.
dro-5H-cyclopropa[5,6]cycloocta[1,2-d]pyridazin-7-yl)methanol Chem., 2013, 11, 6439–6455.
(12). Compound 12 was prepared according to the general pro- 15 W. Chen, D. Wang, C. Dai, D. Hamelberg and B. Wang,
cedure and purified by column chromatography (DCM–MeOH, Chem. Commun., 2012, 48, 1736–1738.
50 : 1) to give a yellow solid (yield, 94%). 1H NMR (CDCl3): 16 J. Sauer, D. K. Heldmann, J. Hetzenegger, J. Krauthan,
1
0.80–0.90 (m, 3H), 1.30–1.40 (m, 2H), 1.55–1.85 (m, 2H)
2.40–2.50 (m, 2H), 2.70–2.80 (m, 2H), 2.88–2.95 (m, 2H), 3.42
H. Sichert and J. Schuster, Eur. J. Org. Chem., 1998, 2885–
2896.
(d, 2H, J = 6.8 Hz), 7.02 (d, 4H, J = 8.8 Hz), 7.48 (d, 4H, J = 17 M. R. Karver, R. Weissleder and S. A. Hilderbrand, Bioconju-
8.8 Hz). HRMS (ESI): m/z calcd for C26H28N2O3 [M + H]+
417.2178, found 417.2180.
gate Chem., 2011, 22, 2263–2270.
18 J. Sauer and D. K. Heldmann, Tetrahedron Lett., 1998, 39,
2549–2552.
4,4′-((6aR,7S,7aS)-7-(Hydroxymethyl)-6,6a,7,7a,8,9-hexahydro-
5H-cyclopropa[5,6]cycloocta[1,2-d]pyridazine-1,4-diyl)bis(2-nitro- 19 H. Neunhoeffer and P. F. Wiley, The Chemistry of Hetero-
phenol) (13). Compound 13 was prepared according to the
cyclic Compounds, Chemistry of 1, 2, 3-Triazines and 1, 2, 4-
general procedure and purified by column chromatography
Triazines, Tetrazines, and Pentazin, Wiley-Interscience, 2009.
(DCM–MeOH, 50 : 1) to give a yellow solid (yield, 92%). 20 J. Yang, M. R. Karver, W. Li, S. Sahu and N. K. Devaraj,
1H NMR (DMSO): 0.70–0.86 (m, 3H), 1.35–1.50 (m, 2H),
Angew. Chem., Int. Ed., 2012, 124, 5312–5315.
2.30–2.40 (m, 2H), 2.65–2.70 (m, 2H), 2.80–3.90 (m, 2H), 3.23 21 L. I. Robins, R. D. Carpenter, J. C. Fettinger,
(d, 2H, J = 6.0 Hz), 7.31 (d, 2H, J = 8.4 Hz), 7.73 (d, 2H, J =
8.4 Hz), 8.02 (s, 2H). HRMS (ESI): m/z calcd for C24H22N4O7
[M + H]+ 479.1567, found 479.1570.
M. J. Haddadin, D. S. Tinti and M. J. Kurth, J. Org. Chem.,
2006, 71, 2480–2485.
22 A. Pinner, Ber. Dtsch. Chem. Ges., 1893, 26, 2126.
23 S. A. Lang, B. D. Johnson and E. Cohen, J. Heterocycl.
Chem., 1975, 12, 1143–1153.
24 W. Skorianetz and E. S. Kovats, Helv. Chim. Acta, 1971, 54,
1922–1939.
Acknowledgements
Financial support from the NIH (GM086925, GM084933, and 25 C. Larsen, E. Binderup and J. Moller, Acta Chem. Scand.,
CA159567) and the Georgia State University Molecular Basis of 1967, 21, 2855–2858.
Disease Program (MBD) through a fellowship to DZW is grate- 26 D. Wang, W. Chen, Y. Zheng, C. Dai, L. Wang and B. Wang,
fully acknowledged.
Heterocycl. Commun., 2013, 19, 171–177.
3954 | Org. Biomol. Chem., 2014, 12, 3950–3955
This journal is © The Royal Society of Chemistry 2014